featured
Eribulin Mesylate Use as Third-Line Therapy in Patients With Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Therapeutic advances in medical oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Eribulin Mesylate Use as Third-Line Therapy in Patients With Metastatic Breast Cancer (VESPRY): A Prospective, Multicentre, Observational Study
Ther Adv Med Oncol 2018 Dec 19;[EPub Ahead of Print], V Adamo, GRR Ricciardi, D Giuffrida, G Scandurra, A Russo, L Blasi, P Spadaro, C Iacono, HJ Soto Parra, A Savarino, F Ferraú, F Zerilli, F Verderame, A Butera, C Santangelo, V Franchina, M CarusoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.